Content about Detoxification

January 12, 2012

Active Health Foods has introduced an energy bar designed for dialysis patients.

RIVERSIDE, Calif. — Active Health Foods has introduced an energy bar designed for dialysis patients.

The Active X double chocolate chip bar is made with an exclusive, proprietary formula and joins the company's current lineup of energy bars sold under the Active X and Active X Plus brands.

October 14, 2011

The Food and Drug Adminsitration has approved a drug made by ApoPharma for a complication resulting from treatments for a genetic condition that causes anemia, the agency said Friday.

SILVER SPRING, Md. — The Food and Drug Adminsitration has approved a drug made by ApoPharma for a complication resulting from treatments for a genetic condition that causes anemia, the agency said Friday.

The FDA announced the approval of Ferriprox (deferiprone), used to treat patients with iron overload due to blood transfusions for thalassemia, a blood disorder. Patients with the disease have excess iron in their bodies because of the frequent blood transfusions they must receive that can lead to iron overload, a condition that can be fatal.

October 25, 2010

Drug maker Keryx Biopharmaceuticals has finished enrolling participants for a late-stage clinical trial of a...

NEW YORK Drug maker Keryx Biopharmaceuticals has finished enrolling participants for a late-stage clinical trial of a drug for patients on kidney dialysis, Keryx said Tuesday.

 

The company is conducting a phase-3 trial of Zerenex (ferric citrate) in patients with end-stage kidney disease on dialysis who have excessive phosphorous levels, a condition known as hyperphosphatemia.

 

 

Keryx said it expects to complete the study and report top-line data by the end of the year.

 

October 13, 2010

The Food and Drug Administration on Thursday warned eight companies that their over-the-counter chelation products...

September 28, 2010

Keryx has begun its phase-3 clinicial trial of a drug designed to treat elevated serum...

NEW YORK Keryx has begun its phase-3 clinicial trial of a drug designed to treat elevated serum phosphorous levels in patients with end-stage renal disease on dialysis.